The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Novel Ocular Drug Delivery Devices Market: Focus on Implants, Inserts and Punctal Plugs - Distribution by Type of Drug Delivery Device, Target Indications (Glaucoma, Retinal Vein Occlusion, Postoperative Ocular Inflammation, Non-Infectious Uveitis, Diabetic Macular Edema, Dry Eye Disease, Wet AMD and Others), Type of Product (Biodegradable and Non-Biodegradable) and Key Geographies (North America, Europe, Asia Pacific and Rest of the World): Industry Trends and Global Forecast, 2021-2030

  • Lowest Price Guaranteed From USD 5,899

  • Published
    September 2021

  • Pages
    201

  • View Count
    277

Example Insights

	Novel-Ocular-Drug-Delivery-Devices-Market-Context Novel-Ocular-Drug-Delivery-Devices-Market-List Novel-Ocular-Drug-Delivery-Devices-Market-Distribution-by-Type
Novel-Ocular-Drug-Delivery-Devices-Market-Insights-from-Primary-Research Novel-Ocular-Drug-Delivery-Devices-Market-Clinical-Research-Landscape Novel-Ocular-Drug-Delivery-Devices-Market-Partnerships-and-Collaborations
Novel-Ocular-Drug-Delivery-Devices-Market-Funding-and-Investments Novel-Ocular-Drug-Delivery-Devices-Market-Patent-Analysis Novel-Ocular-Drug-Delivery-Devices-Market-Distribution-by-Geography

 

Overview

According to the World Health Organization (WHO), more than 2.2 billion individuals across the world suffer from some degree of vision impairment caused due to various ophthalmic disorders, such as glaucoma, trachoma, cataract, diabetic retinopathy and wet age-related macular degeneration. Around 50% of the cases are left either unaddressed and / or could have been prevented. It is also worth highlighting that around 1.7 billion individuals worldwide are expected to lose their vision by 2050. As per the Centers for Disease Control and Prevention (CDC), loss of vision can pose an economic burden of over USD 35 billion, in terms of loss of productivity and direct costs of treatment / care. Considering the aforementioned facts, there is a rise in demand for effective therapeutic interventions for the treatment of ocular diseases, in order to prevent complete vision loss. Conventionally, ocular diseases have been treated through surgery, laser or pharmacological interventions (such as anti-angiogenic drugs). However, these treatment options are associated with several limitations, including side effects of intravitreal injections and conventional surgeries, poor drug bioavailability at the target tissue site and need for frequent drug administration to maintain efficacy for a longer duration. In addition, at present, more than 90% of the marketed ophthalmic formulations are available in the form of eye drops that mainly target diseases related to anterior segment of the eye. Studies suggest that, if administered with the help of topical eye drops, around 95% of the drug is lost due to a number of challenges, such as dilution of product by tears and permeation issues related to cornea. Therefore, drug delivery formulations, such as eye drops and ointments, cannot be considered as an optimal treatment option for vision-threatening diseases.

Owing to the aforementioned concerns, there is an evident rise in the demand for effective, non-invasive drug delivery systems that are capable of overcoming bioavailability hurdles and enable delivery of the drug at the target cells, at effective concentrations, for a suitable period of time. Over time, several pharmaceutical companies across the world have undertaken various initiatives to develop novel drug delivery devices, such as sustained release implants, ocular inserts and punctal plugs, that are capable of enabling effective administration of drugs, while overcoming the existing challenges. In fact, over 1,100 patents related to novel ocular drug delivery devices have been filed / granted in the past few years, demonstrating the continued innovation being carried out in this domain. The growing interest of pharmaceutical stakeholders in this field is also reflected from the recent rise in partnership activity of novel ocular drug delivery device developers. Driven by the increasing patient population and introduction of novel and advanced ocular drug delivery devices, this market is anticipated to witness steady growth in the coming years.

Scope of the Report

The “Novel Ocular Drug Delivery Devices Market by Type of Drug Delivery Device (Implants, Inserts and Punctal Plugs), Target Indications (Glaucoma, Retinal Vein Occlusion, Postoperative Ocular Inflammation, Non-Infectious Uveitis, Diabetic Macular Edema, Dry Eye Disease, Wet Age-related Macular Degeneration, Retinal Diseases, Neovascular Age-Related Macular Degeneration and Others), Type of Product (Biodegradable and Non-biodegradable) and Key Geographies (North America, Europe, Asia Pacific and Rest of the World): Industry Trends and Global Forecasts, 2021-2030” report features an extensive study of the current market landscape and the likely adoption of novel ocular drug delivery devices, over the next decade.  The study features a detailed analysis of the key drivers and trends related to this evolving domain. Amongst other elements, the report includes:

  • A detailed assessment of the current market landscape of novel ocular drug delivery devices, with respect to type of drug delivery device (implants, inserts and punctal plugs), current status of development (marketed, phase III, phase II, phase I / II, phase I and preclinical), type of product (biodegradable and non-biodegradable), type of molecule (small molecules and biologics), target indication (glaucoma, retinal vein occlusion, postoperative ocular inflammation, non-infectious uveitis, diabetic macular edema, dry eye disease, wet age-related macular degeneration, retinal diseases, neovascular age-related macular degeneration and others) and route of administration (topical, intravitreal, intracameral, intracanalicular, implantable and subconjunctival). In addition, the chapter lists novel ocular drug delivery device developers, along with information on their respective year of establishment, company size, location of headquarters and most active players (in terms of number of devices).
  • Elaborate profiles of key players that are engaged in the development of novel ocular drug delivery devices. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives), information on technology use, respective product portfolio, recent developments and an informed future outlook.
  • An in-depth analysis of completed, ongoing and planned clinical studies of various novel ocular drug delivery devices based on relevant parameters, such as trial registration year, trial recruitment status, phase of development, study design, target patient segment, target indication, type of sponsor, most active players (in terms of number of registered trials conducted) and key geographical regions.
  • An analysis of the partnerships that have been established in this domain during the period 2012-2021 covering R&D agreements, product commercialization agreements, product development and commercialization agreements, product distribution agreements, technology licensing agreements, product development agreements, acquisitions, product licensing agreements and other related agreements.
  • An analysis of the investments that have been made into companies with proprietary novel ocular drug delivery devices, including seed financing, venture capital financing, capital raised from IPOs and subsequent offerings, grants and debt financing.The investment instances have been analyzed based on various relevant parameters, such as year of investment, amount invested, type of funding, most active players (in terms of number of funding instances) and type of investor.
  • An in-depth analysis of over 1,100 patents filed / granted related to novel ocular drug delivery devices, till 2021. The instances have been analyzed based on various relevant parameters, such as type of patent, publication year, regional applicability, CPC symbols, emerging focus areas, type of drug delivery device, type of applicant, leading patent assignees (in terms of number of patents filed / granted), patent benchmarking and valuation.  
  • A case study on the available novel ocular drug delivery devices such as bionic eye, intraocular lenses, eye-drop dispensers and others.

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for novel ocular drug delivery devices over the coming decade. Additionally, it features market size projections for the overall novel ocular drug delivery devices market, wherein both the current and upcoming opportunity is segmented across [A] type of drug delivery device (implants, inserts and punctal plugs), [B] target indications (glaucoma, retinal vein occlusion, postoperative ocular inflammation, non-infectious uveitis, diabetic macular edema, dry eye disease, wet age-related macular degeneration, retinal diseases, neovascular age-related macular degeneration and others), [C] type of product (biodegradable  and non-biodegradable) and [D] key geographies (North America, Europe, Asia Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely the conservative, base and optimistic scenarios, which represent different tracks of the industry’s evolution.
 
The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

  • Eyal Sheetrit (Chief Executive Officer and President, Eximore)
  • Murty Vyakarnam (Chief Executive Officer and Co-founder, Oculinea)

Key Questions Answered

  • Who are the leading novel ocular drug delivery device developers?
  • Which are the popular types of novel ocular drug delivery devices available in this market?
  • What are the key challenges faced by stakeholders engaged in this domain?
  • What types of partnership models are commonly being adopted by stakeholders in this industry? 
  • Who are the key investors in this domain? 
  • How is the intellectual property landscape in this field likely to evolve in the foreseen future?
  • What are the factors that are likely to influence the evolution of this market?         
  • How is the current and future market opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured during our research. It offers a high-level view on the likely evolution of the novel ocular drug delivery devices market in the short to mid-term and long term.

Chapter 3 provides a general overview of the structure of eye and its associated routes of drug administration. Additionally, it provides information on the popular ocular drug delivery systems (dendrimers, hydrogels, liposomes, nanomicelles and nanoparticles). 

Chapter 4 includes detailed assessment on  novel ocular drug delivery devices that are currently approved or are in different stages of development. It features a comprehensive analysis of novel ocular drug delivery devices with respect to type of drug delivery device (implants, inserts and punctal plugs), current status of development (marketed, phase III, phase II, phase I/II, phase I and preclinical), type of product (biodegradable and non-biodegradable), type of molecule (small molecules and biologics), target indication (glaucoma, retinal vein occlusion, postoperative ocular inflammation, non-infectious uveitis, diabetic macular edema, dry eye disease, wet age-related macular degeneration, retinal diseases, neovascular age-related macular degeneration and others) and route of administration (topical, intravitreal, intracameral, intracanalicular, implantable and subconjunctival). In addition, the chapter lists novel ocular drug delivery device developers, along with information on their respective year of establishment, company size, location of headquarters and most active players (in terms of number of devices).

Chapter 5 provides detailed case study on the available novel ocular drug delivery devices such as bionic eye, intraocular lenses, eye-drop dispensers, and others.

Chapter 6 includes detailed profiles of key players that are engaged in the development of novel ocular drug delivery devices. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives), information on technology use, respective product portfolio, recent developments and an informed future outlook.

Chapter 7 presents an in-depth analysis of completed, ongoing and planned clinical studies of various novel ocular drug delivery devices based on relevant parameters, such as trial registration year, trial recruitment status, phase of development, study design, target patient segment, target indication, type of sponsor, most active players (in terms of number of registered trials conducted) and key geographical regions.

Chapter 8 features an elaborate discussion and analysis of the various collaborations and partnerships that have been inked amongst players in this market, during the period 2012-2021 . Further, the partnership activity in this domain has been analyzed based on various parameters, such as year of partnership, type of partnership model (R&D agreements, product commercialization agreements, product development and commercialization agreements, product distribution agreements, technology licensing agreements, product development agreements, acquisitions, product licensing agreements and others), and regional distribution of the collaborations.

Chapter 9 provides details on the various investments that have been made into companies with proprietary novel ocular drug delivery devices, including seed financing, venture capital financing, capital raised from IPOs and subsequent offerings, grants and debt financing. The investment instances have been analyzed based on various relevant parameters, such as year of investment, amount invested, type of funding, most active players (in terms of number of funding instances) and type of investor.

Chapter 10 provides an in-depth over 1,100 patents filed / granted related to novel ocular drug delivery devices, till 2021. The instances have been analyzed based on various relevant parameters, such as type of patent, publication year, regional applicability, CPC symbols, emerging focus areas, type of drug delivery device, type of applicant, leading patent assignees (in terms of number of patents filed / granted), patent benchmarking and valuation.  

Chapter 11 presents an insightful market forecast analysis, highlighting the future potential of novel till the year 2030. In order to provide details on the future opportunity, our projections have been segmented across important market segments, namely [A] type of drug delivery device (implants, inserts and punctal plugs), [B] target indication (glaucoma, retinal vein occlusion, postoperative ocular inflammation, non-infectious uveitis, diabetic macular edema, dry eye disease, wet age-related macular degeneration, retinal diseases, neovascular age-related macular degeneration and others), [C] type of product (biodegradable  and non-biodegradable) and [D] key geographies (North America, Europe, Asia Pacific and rest of the world).

Chapter 12 summarizes the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 13 provides the transcripts of interviews conducted with key stakeholders of this market. In this chapter, we have presented the details of our conversation with Eyal Sheetrit (Chief Executive Officer and President, Eximore) and Murty Vyakarnam (Chief Executive Officer and Co-founder, Oculinea).

Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 15 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Structure of the Eye
3.3. Routes for Ocular Drug Delivery 
3.4. Ocular Drug Delivery Systems 
3.4.1. Dendrimers
3.4.2. Hydrogels
3.4.3. Liposomes
3.4.4. Nanomicelles
3.4.5. Nanoparticles
3.5. Concluding Remarks

4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Novel Ocular Drug Delivery Devices: Overall Market Landscape
4.2.1. Analysis by Type of Drug Delivery Device
4.2.2. Analysis by Current Status of Development
4.2.3. Analysis by Type of Drug Delivery Device and Current Status of Development
4.2.4. Analysis by Type of Product
4.2.5. Analysis by Type of Drug Delivery Device and Type of Product
4.2.6. Analysis by Type of Molecule
4.2.7. Analysis by Target Indication
4.2.8. Analysis by Route of Administration

4.3. Novel Ocular Drug Delivery Devices: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Key Industry Players: Analysis by Number of Devices

5. CASE STUDY: TYPES OF NOVEL OCULAR DRUG DELIVERY DEVICES
5.1. Chapter Overview
5.2. Novel Ocular Drug Delivery Devices
5.2.1. Bionic Eye
5.2.1.1. Working of a Bionic Eye

5.2.2. Intra Ocular Lenses
5.2.2.1. Evolution of Intra Ocular Lenses
5.2.2.2. Applications of Intra Ocular Lenses
5.2.2.3. Types of Intra Ocular Lenses
5.2.2.4. Classification of Intra Ocular Lenses

5.2.3. Eye Drop Dispenser Devices
5.3. Other Novel Ocular Drug Delivery Systems

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Alimera Sciences
6.2.1. Company Overview
6.2.2. Technology Overview
6.2.3. Product Portfolio
6.2.4. Recent Developments and Future Outlook

6.3. Bausch and Lomb
6.3.1. Company Overview
6.3.2. Technology Overview
6.3.3. Product Portfolio
6.3.4. Recent Developments and Future Outlook

6.4. EyePoint Pharmaceuticals
6.4.1. Company Overview
6.4.2. Technology Overview 
6.4.3. Product Portfolio
6.4.4. Recent Developments and Future Outlook

6.5. Genentech
6.5.1. Company Overview
6.5.2. Technology Overview
6.5.3. Product Portfolio
6.5.4. Recent Developments and Future Outlook

6.6. Glaukos
6.6.1. Company Overview
6.6.2. Technology Overview
6.6.3. Product Portfolio
6.6.4. Recent Developments and Future Outlook

6.7. Neurotech Pharmaceuticals
6.7.1. Company Overview
6.7.2. Technology Overview
6.7.3. Product Portfolio
6.7.4. Recent Developments and Future Outlook

6.8. Ocular Therapeutix
6.8.1. Company Overview
6.8.2. Technology Overview
6.8.3. Product Portfolio
6.8.4. Recent Developments and Future Outlook

7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Novel Ocular Drug Delivery Devices: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2 Analysis by Trial Phase
7.3.3. Analysis by Trial Recruitment Status
7.3.4. Analysis by Trial Registration Year and Enrolled Patient Population
7.3.5. Analysis by Enrolled Patient Population and Phase of Development
7.3.6. Analysis by Study Design
7.3.7. Analysis by Target Patient Segment
7.3.8. Analysis by Target Indication
7.3.9. Analysis by Type of Sponsor
7.3.10. Most Active Players: Analysis by Number of Registered Trials
7.3.11. Analysis by Number of Registered Trials and Geography

8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Novel Ocular Drug Delivery Devices: Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year and Type of Partnership
8.3.4. Most Active Players: Analysis by Number of Partnerships
8.3.5. Analysis by Geography
8.3.5.1. Region-wise Distribution
8.3.5.2. Country-wise Distribution

9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Type of Funding
9.3. Novel Ocular Drug Delivery Devices Market: Funding and Investment Analysis
9.3.1. Analysis by Year of Investment
9.3.2. Analysis by Amount Invested
9.3.3. Analysis by Type of Funding
9.3.4. Analysis of Amount Invested by Type of Funding 
9.3.5. Most Active Players: Analysis by Number of Funding Instances
9.3.6. Analysis by Type of Investor
9.3.7. Most Active Investors: Analysis by Number of Funding Instances
9.3.8. Analysis by Geography

10. PATENT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Novel Ocular Drug Delivery Devices: Patent Analysis
10.3.1. Analysis by Publication Year
10.3.2. Analysis by Geography
10.3.3. Analysis by CPC Symbols
10.3.4 Emerging Focus Areas
10.3.5. Analysis by Type of Drug Delivery Device
10.3.6. Analysis by Type of Applicant
10.3.7. Leading Players: Analysis by Number of Patents

10.4. Novel Ocular Drug Delivery Devices: Patent Benchmarking Analysis
10.4.1 Analysis by Patent Characteristics
10.5. Novel Ocular Drug Delivery Devices: Patent Valuation Analysis
10.6. Leading Patents: Analysis by Number of Citations

11. MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Forecast Methodology and Key Assumptions
11.3. Global Novel Ocular Drug Delivery Devices Market, 2021-2030
11.3.1. Novel Ocular Drug Delivery Devices Market, 2021-2030: Distribution by Type of Drug Delivery Device
11.3.1.1. Novel Ocular Drug Delivery Devices Market for Implants, 2021-2030
11.3.1.2. Novel Ocular Drug Delivery Devices Market for Inserts, 2021-2030
11.3.1.3. Novel Ocular Drug Delivery Devices Market for Punctal Plugs, 2021-2030

11.3.2. Novel Ocular Drug Delivery Devices Market, 2021-2030: Distribution by Target Indication

11.3.3. Novel Ocular Drug Delivery Devices Market, 2021-2030: Distribution by Type of Product
11.3.4. Novel Ocular Drug Delivery Devices Market, 2021-2030: Distribution by Geography
11.3.4.1. Novel Ocular Drug Delivery Devices Market in North America, 2021-2030
11.3.4.1.1. Novel Ocular Drug Delivery Devices Market for Implants in North America, 2021-2030
11.3.4.1.2. Novel Ocular Drug Delivery Devices Market for Inserts in North America, 2021-2030
11.3.4.1.3. Novel Ocular Drug Delivery Devices Market for Punctal Plugs in North America, 2021-2030

11.3.4.2. Novel Ocular Drug Delivery Devices Market in Europe, 2021-2030
11.3.4.2.1. Novel Ocular Drug Delivery Devices Market for Implants in Europe, 2021-2030
11.3.4.2.2. Novel Ocular Drug Delivery Devices Market for Inserts in Europe, 2021-2030
11.3.4.2.3. Novel Ocular Drug Delivery Devices Market for Punctal Plugs in Europe, 2021-2030

11.3.4.3. Novel Ocular Drug Delivery Devices Market in Asia Pacific, 2021-2030
11.3.4.3.1. Novel Ocular Drug Delivery Devices Market for Implants in Asia Pacific, 2021-2030
11.3.4.3.2. Novel Ocular Drug Delivery Devices Market for Inserts in Asia Pacific, 2021-2030
11.3.4.3.3. Novel Ocular Drug Delivery Devices Market for Punctal Plugs in Asia Pacific, 2021-2030

11.3.4.4. Novel Ocular Drug Delivery Devices Market Rest of the World, 2021-2030
11.3.4.4.1. Novel Ocular Drug Delivery Devices Market for Implants in Rest of the World, 2021-2030
11.3.4.4.2. Novel Ocular Drug Delivery Devices Market for Inserts in Rest of the World, 2021-2030
11.3.4.4.3. Novel Ocular Drug Delivery Devices Market for Punctal Plugs in Rest of the World, 2021-2030

12. CONCLUDING REMARKS

13. EXECUTIVE INSIGHTS
13.1. Chapter Overview
13.2. Eximore
13.2.1. Company Snapshot
13.2.2. Interview Transcript: Eyal Sheetrit, Co-Founder and Chief Executive Officer

13.3. Oculinea
13.3.1. Company Snapshot
13.3.2. Interview Transcript: Murty Vyakarnam, Co-Founder and Chief Executive  
Officer 

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Overview of Market Landscape and Developer Landscape
Figure 2.2 Executive Summary: Clinical Trial Activity and Partnership Activity
Figure 2.3 Executive Summary: Funding and Investment Analysis and Patent Analysis
Figure 2.4 Executive Summary: Market Forecast
Figure 3.1 Structure of the Eye
Figure 3.2 Layers of Tissues in the Eye
Figure 3.3 Types of Ocular Drug Delivery Systems
Figure 3.4 Marketed Ocular Drug Delivery Implants
Figure 4.1 Novel Ocular Drug Delivery Devices: Distribution by Type of Drug Delivery Device
Figure 4.2 Novel Ocular Drug Delivery Devices: Distribution by Current Status of Development
Figure 4.3 Novel Ocular Drug Delivery Devices: Distribution by Type of Drug Delivery Device and Current Status of Development
Figure 4.4 Novel Ocular Drug Delivery Devices: Distribution by Type of Product
Figure 4.5 Novel Ocular Drug Delivery Devices: Distribution by Type of Drug Delivery Device and Type of Product
Figure 4.6 Novel Ocular Drug Delivery Devices: Distribution by Type of Molecule
Figure 4.7 Novel Ocular Drug Delivery Devices: Distribution by Target Indication
Figure 4.8 Novel Ocular Drug Delivery Devices: Distribution by Route of Administration
Figure 4.9 Novel Ocular Drug Delivery Device Developers: Distribution by Year of Establishment
Figure 4.10 Novel Ocular Drug Delivery Device Developers: Distribution by Company Size
Figure 4.11 Novel Ocular Drug Delivery Device Developers: Distribution by Location of Headquarters
Figure 4.12 Key Industry Players: Distribution by Number of Devices
Figure 5.1 Bionic Eye: External and Implantable Modules
Figure 5.2 Visual Prosthesis: Mode of Operation
Figure 5.3 Evolution of Intraocular Lenses
Figure 5.4 Applications of Bandage Intraocular Lenses
Figure 7.1 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2011-2021
Figure 7.2 Clinical Trial Analysis: Distribution by Phase of Development
Figure 7.3 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Figure 7.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Recruitment Status, Pre-2011 - 2021
Figure 7.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
Figure 7.6 Clinical Trial Analysis: Distribution by Enrolled Patient Population and Phase of Development
Figure 7.7 Clinical Trial Analysis: Distribution by Study Design
Figure 7.8 Clinical Trial Analysis: Distribution by Target Patient Segment
Figure 7.9 Clinical Trial Analysis: Distribution by Target Indication
Figure 7.10 Clinical Trial Analysis: Distribution by Type of Sponsor
Figure 7.11 Most Active Players: Distribution by Number of Registered Trials
Figure 7.12 Clinical Trial Analysis: Distribution by Geography
Figure 8.1 Partnerships and Collaborations: Cumulative Distribution by Year, 2012-2021
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 8.4 Most Active Players: Distribution by Number of Partnerships
Figure 8.5 Partnerships and Collaborations: Distribution by Region
Figure 8.6 Partnerships and Collaborations: Distribution by Country
Figure 9.1 Funding and Investment Analysis: Cumulative Year-wise Trend of Funding Instances, Pre-2011-2021
Figure 9.2 Funding and Investment Analysis: Cumulative Distribution of Amount Invested by Year (USD Million)
Figure 9.3 Funding and Investment Analysis: Distribution by Type of Funding
Figure 9.4 Funding and Investment Analysis: Distribution by Total Amount Invested and Type of Funding (USD Million)
Figure 9.5 Funding and Investment Analysis: Heat-map Representation of Amount Invested and Type of Funding (USD Million)
Figure 9.6 Most Active Players: Distribution by Number of Funding Instances
Figure 9.7 Funding and Investment Analysis: Distribution by Type of Investor
Figure 9.8 Most Active Investors: Distribution by Number of Funding Instances
Figure 9.9 Funding and Investment Analysis: Distribution by Geography
Figure 10.1 Patent Analysis: Distribution by Patent Filed
Figure 10.2 Patent Analysis: Distribution by Year of Publication, 2002-2021
Figure 10.3 Patent Analysis: Distribution by Location of Patent Jurisdiction
Figure 10.4 Patent Analysis: Distribution by Jurisdiction
Figure 10.5 Patent Analysis: Distribution by CPC Symbols
Figure 10.6 Patent Analysis: Emerging Focus Areas
Figure 10.7 Patent Analysis: Distribution by Type of Drug Delivery Device
Figure 10.8 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Figure 10.9 Leading Industry Players: Distribution by Number of Patents
Figure 10.10 Leading Non-Industry Players: Distribution by Number of Patents
Figure 10.11 Leading Patent Assignees: Distribution by Number of Patents
Figure 10.12 Patent Benchmarking Analysis: Distribution of Leading Industry Player by Patent Characteristics (CPC Symbols)
Figure 10.13 Patent Analysis: Distribution by Patent Age
Figure 10.14 Novel Ocular Drug Delivery Devices: Patent Valuation
Figure 11.1 Global Novel Ocular Drug Delivery Devices Market, 2021-2030 (USD Million)
Figure 11.2 Novel Ocular Drug Delivery Market for Implants, 2021-2030 (USD Million)
Figure 11.3 Novel Ocular Drug Delivery Market for Inserts, 2021-2030 (USD Million)
Figure 11.4 Novel Ocular Drug Delivery Market for Punctal Plugs, 2021-2030 (USD Million)
Figure 11.5 Novel Ocular Drug Delivery Devices Market, 2021 and 2030: Distribution by Target Indication (USD Million)
Figure 11.6 Novel Ocular Drug Delivery Devices Market, 2021 and 2030: Distribution by Type of Product (USD Million)
Figure 11.7 Novel Ocular Drug Delivery Devices Market, 2021 and 2030: Distribution by Geography (USD Million)
Figure 11.8 Novel Ocular Drug Delivery Devices Market in North America, 2021-2030 (USD Million)
Figure 11.9 Novel Ocular Drug Delivery Devices Market for Implants in North America, 2021-2030 (USD Million)
Figure 11.10 Novel Ocular Drug Delivery Devices Market for Inserts in North America, 2021-2030 (USD Million)
Figure 11.11 Novel Ocular Drug Delivery Devices Market for Punctal Plugs in North America, 2021-2030 (USD Million)
Figure 11.12 Novel Ocular Drug Delivery Devices Market in Europe, 2021-2030 (USD Million)
Figure 11.13 Novel Ocular Drug Delivery Devices Market for Implants in Europe, 2021-2030 (USD Million)
Figure 11.14 Novel Ocular Drug Delivery Devices Market for Inserts in Europe, 2021-2030 (USD Million)
Figure 11.15 Novel Ocular Drug Delivery Devices Market for Punctal Plugs in Europe, 2021-2030 (USD Million)
Figure 11.16 Novel Ocular Drug Delivery Devices Market in Asia Pacific, 2021-2030 (USD Million)
Figure 11.17 Novel Ocular Drug Delivery Devices Market for Implants in Asia Pacific, 2021-2030 (USD Million)
Figure 11.18 Novel Ocular Drug Delivery Devices Market for Inserts in Asia Pacific, 2021-2030 (USD Million)
Figure 11.19 Novel Ocular Drug Delivery Devices Market for Punctal Plugs in Asia Pacific, 2021-2030 (USD Million)
Figure 11.20 Novel Ocular Drug Delivery Devices Market in Rest of the World, 2021-2030 (USD Million)
Figure 11.21 Novel Ocular Drug Delivery Devices Market for Implants in Rest of the World, 2021-2030 (USD Million)
Figure 11.22 Novel Ocular Drug Delivery Devices Market for Inserts in Rest of the World, 2021-2030 (USD Million)
Figure 11.23 Novel Ocular Drug Delivery Devices Market for Punctal Plugs in Rest of the World, 2021-2030 (USD Million)
Figure 12.1 Concluding Remarks: Overall Market Landscape
Figure 12.2 Concluding Remarks: Clinical Trial Analysis
Figure 12.3 Concluding Remarks: Partnerships and Collaborations
Figure 12.4 Concluding Remarks: Funding and Investment Analysis
Figure 12.5 Concluding Remarks: Market Forecast

List Of Tables

Table 3.1 Routes for Ocular Drug Delivery
Table 4.1 Novel Ocular Drug Delivery: Overall Market Landscape
Table 4.2 Novel Ocular Drug Delivery Devices: List of Developers
Table 5.1 Bionic Eye Systems: Information on Device Developer, Headquarters, Target Indication and Site of Implant Placement
Table 5.2 Advantages and Disadvantages of Different Types of Intraocular Lenses
Table 5.3 Therapeutic Intraocular Lenses: Information on Developer, Headquarters, Target Indication and Type of product
Table 5.4 Eye-Drop Dispenser Devices: Information on Developer, Headquarters and Target Site
Table 5.5 Other Novel Ocular Drug Delivery Devices: Information on Technology, Type of Product, Developer, Year of Establishment, Company Size and Headquarters
Table 6.1 List of Companies Profiled
Table 6.2 Alimera Sciences: Company Overview
Table 6.3 Alimera Sciences: Technology Overview
Table 6.4 Alimera Sciences: Product Portfolio
Table 6.5 Alimera Sciences: Recent Developments and Future Outlook
Table 6.6 Bausch and Lomb: Company Overview
Table 6.7 Bausch and Lomb: Technology Overview
Table 6.8 Bausch and Lomb: Product Portfolio
Table 6.9 Bausch and Lomb: Recent Developments and Future Outlook
Table 6.10 EyePoint Pharmaceuticals: Company Overview
Table 6.11 EyePoint Pharmaceuticals: Technology Overview
Table 6.12 EyePoint Pharmaceuticals: Product Portfolio
Table 6.13 EyePoint Pharmaceuticals: Recent Developments and Future Outlook
Table 6.14 Genentech: Company Overview
Table 6.15 Genentech: Technology Overview
Table 6.16 Genentech: Product Portfolio
Table 6.17 Glaukos: Company Overview
Table 6.18 Glaukos: Technology Overview
Table 6.19 Glaukos: Product Portfolio
Table 6.20 Glaukos: Recent Developments and Future Outlook
Table 6.21 Neurotech Pharmaceuticals: Company Overview
Table 6.22 Neurotech Pharmaceuticals: Technology Overview
Table 6.23 Neurotech Pharmaceuticals: Product Portfolio
Table 6.24 Ocular Therapeutix: Company Overview
Table 6.25 Ocular Therapeutix: Technology Overview
Table 6.26 Ocular Therapeutix: Product Portfolio
Table 6.27 Ocular Therapeutix: Recent Developments and Future Outlook
Table 7.1 Novel Ocular Drug Delivery Devices: List of Clinical Trials
Table 8.1 Novel Ocular Drug Delivery Devices: List of Partnerships and Collaborations, 2012-2021
Table 9.1 Novel Ocular Drug Delivery Devices: Funding and Investments, Pre-2011-2021
Table 9.2 Novel Ocular Drug Delivery Devices: Summary of Investments
Table 10.1 Patent Analysis: Prominent CPC Symbols
Table 10.2 Patent Analysis: Most Popular CPC Symbols
Table 10.3 Patent Analysis: List of Top CPC Symbols
Table 10.4 Patent Analysis: Summary of Benchmarking Analysis
Table 10.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 10.6 Patent Portfolio: List of Leading Patents (In terms of Highest Relative Valuation)
Table 10.7 Patent Portfolio: List of Leading Patents (In terms of Number of Citations)
Table 13.1 Eximore: Company Snapshot
Table 13.2 Oculinea: Company Snapshot
Table 14.1 Novel Ocular Drug Delivery Devices: Distribution by Type of Drug Delivery Device
Table 14.2 Novel Ocular Drug Delivery Devices: Distribution by Current Status of Development
Table 14.3 Novel Ocular Drug Delivery Devices: Distribution by Type of Drug Delivery Device and Current Status of Development
Table 14.4 Novel Ocular Drug Delivery Devices: Distribution by Type of Product
Table 14.5 Novel Ocular Drug Delivery Devices: Distribution by Type of Drug Delivery Device and Type of Product
Table 14.6 Novel Ocular Drug Delivery Devices: Distribution by Type of Molecule
Table 14.7 Novel Ocular Drug Delivery Devices: Distribution by Target Indication
Table 14.8 Novel Ocular Drug Delivery Devices: Distribution by Route of Administration
Table 14.9 Novel Ocular Drug Delivery Device Developers: Distribution by Year of Establishment
Table 14.10 Novel Ocular Drug Delivery Device Developers: Distribution by Company Size
Table 14.11 Novel Ocular Drug Delivery Device Developers: Distribution by Location of Headquarters
Table 14.12 Key Industry Players: Distribution by Number of Devices
Table 14.13 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2011-2021
Table 14.14 Clinical Trial Analysis: Distribution by Phase of Development
Table 14.15 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Table 14.16 Clinical Trial Analysis: Distribution by Trial Registration Year and Recruitment Status, Pre-2011-2021
Table 14.17 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
Table 14.18 Clinical Trial Analysis: Distribution by Enrolled Patient Population and Phase of Development
Table 14.19 Clinical Trial Analysis: Distribution by Study Design
Table 14.20 Clinical Trial Analysis: Distribution by Target Patient Segment
Table 14.21 Clinical Trial Analysis: Distribution by Target Indication
Table 14.22 Clinical Trial Analysis: Distribution by Type of Sponsor
Table 14.23 Most Active Players: Distribution by Number of Registered Trials
Table 14.24 Clinical Trial Analysis: Distribution by Geography
Table 14.25 Partnerships and Collaborations: Cumulative Distribution by Year, 2012-2021
Table 14.26 Partnerships and Collaborations: Distribution by Type of Partnership
Table 14.27 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 14.28 Most Active Players: Distribution by Number of Partnerships
Table 14.29 Partnerships and Collaborations: Distribution by Region
Table 14.30 Partnerships and Collaborations: Distribution by Country
Table 14.31 Funding and Investment Analysis: Cumulative Year-wise Trend of Funding Instances, Pre-2011-2021
Table 14.32 Funding and Investment Analysis: Cumulative Distribution by Amount Invested and Year (USD Million)
Table 14.33 Funding and Investment Analysis: Distribution by Type of Funding
Table 14.34 Funding and Investment Analysis: Distribution by Total Amount Invested and Type of Funding (USD Million)
Table 14.35 Funding and Investment Analysis: Heat-map Representation of Amount Invested and Type of Funding, Pre-2011-2021(USD Million)
Table 14.36 Most Active Players: Distribution by Number of Funding Instances
Table 14.37 Funding and Investment Analysis: Distribution by Type of Investor
Table 14.38 Most Active Investors: Distribution by Number of Funding Instances
Table 14.39 Funding and Investment Analysis: Distribution by Geography
Table 14.40 Patent Analysis: Distribution by Type of Patent
Table 14.41 Patent Analysis: Distribution by Year of Publication, 2002-2021
Table 14.42 Patent Analysis: Distribution by Geography
Table 14.43 Patent Analysis: Distribution by Jurisdiction
Table 14.44 Patent Analysis: Distribution by CPC Symbols
Table 14.45 Patent Analysis: Distribution by Type of Drug Delivery Device
Table 14.46 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Table 14.47 Leading Industry Players: Distribution by Number of Patents
Table 14.48 Leading Non-Industry Players: Distribution by Number of Patents
Table 14.49 Leading Patent Assignees: Distribution by Number of Patents
Table 14.50 Patent Analysis: Distribution by Patent Age
Table 14.51 Novel Ocular Drug Delivery Devices: Patent Valuation
Table 14.52 Global Novel Ocular Drug Delivery Devices Market, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.53 Novel Ocular Drug Delivery Market for Implants, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.54 Novel Ocular Drug Delivery Market for Inserts, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.55 Novel Ocular Drug Delivery Market for Punctal Plugs, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.56 Novel Ocular Drug Delivery Devices Market, 2021 and 2030: Distribution by Target Indication (USD Million)
Table 14.57 Novel Ocular Drug Delivery Devices Market, 2021 and 2030: Distribution by Type of Product (USD Million)
Table 14.58 Novel Ocular Drug Delivery Devices Market, 2021 and 2030: Distribution by Geography (USD Million)
Table 14.59 Novel Ocular Drug Delivery Devices Market in North America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.60 Novel Ocular Drug Delivery Devices Market for Implants in North America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.61 Novel Ocular Drug Delivery Devices Market for Inserts in North America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.62 Novel Ocular Drug Delivery Devices Market for Punctal Plugs in North America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.63 Novel Ocular Drug Delivery Devices Market in Europe, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.64 Novel Ocular Drug Delivery Devices Market for Implants in Europe, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.65 Novel Ocular Drug Delivery Devices Market for Inserts in Europe, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.66 Novel Ocular Drug Delivery Devices Market for Punctal Plugs in Europe, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.67 Novel Ocular Drug Delivery Devices Market in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.68 Novel Ocular Drug Delivery Devices Market for Implants in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.69 Novel Ocular Drug Delivery Devices Market for Inserts in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.70 Novel Ocular Drug Delivery Devices Market for Punctal Plugs in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.71 Novel Ocular Drug Delivery Devices Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.72 Novel Ocular Drug Delivery Devices Market for Implants in Rest of the World, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.73 Novel Ocular Drug Delivery Devices Market for Inserts in Rest of the World, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.74 Novel Ocular Drug Delivery Devices Market for Punctal Plugs in Rest of the World, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)

List Of Companies

The following companies and organizations have been mentioned in the report.

  1. 20/20 OptimEyes Technologies
  2. 23andMe
  3. Aciont
  4. AcuFocus 
  5. Adaptive Biotechnologies
  6. Aerie Pharmaceuticals
  7. Aero Pump
  8. AffaMed Therapeutics
  9. Akarna Therapeutics
  10. Alcon
  11. Alcon
  12. Alibaba Health Information Technology
  13. Alimera Sciences
  14. Allergan
  15. Alta Partners
  16. Amorphex Therapeutics
  17. Angiotech Pharmaceuticals
  18. Anthrogenesis
  19. Ascension Ventures
  20. Atalanta
  21. Avedro
  22. Avizorex Pharma 
  23. Bausch & Lomb
  24. Brien Holden Vision Institute (BHVI)
  25. BioHealthWays 
  26. Bionic Vision Technologies
  27. Brandon Capital partners 
  28. BTG 
  29. Burrill & Company
  30. Cella Therapeutics
  31. Children's National Hospital
  32. ChromaGen Vision
  33. Cirle
  34. Clarus Ventures
  35. Clearside Biomedical
  36. Corporate Renaissance Group
  37. D. Western Therapeutics Institute
  38. Deerfield
  39. DelSiTech
  40. Department of Defense
  41. Domain Associates
  42. DSM 
  43. Envisia Therapeutics
  44. Escalon Medical
  45. EW Healthcare Partners
  46. Eximore
  47. EYE-GO
  48. EyePoint Pharmaceuticals
  49. Eyevensys
  50. FB VISION
  51. Fjord Ventures
  52. Foundry Therapeutics 
  53. Frazier Healthcare Partners
  54. Genentech
  55. Genesis Therapeutics
  56. Glaukos
  57. Graybug Vision
  58. Gund Investment
  59. Gyroscope Therapeutics
  60. Heptares Therapeutics
  61. Horizon Discovery 
  62. Horus Pharma
  63. IDVentures
  64. IDA Ireland
  65. Imbio
  66. ImprimisRx 
  67. Incept
  68. InterWest Partners
  69. Intratus
  70. Invest Michigan
  71. IQVIA
  72. Johnson & Johnson Vision
  73. Kala Pharmaceuticals
  74. Kedalion Therapeutics
  75. Kineta
  76. Knight Therapeutics
  77. Kodiak Sciences
  78. Laboratoires Thea
  79. Laurus Labs 
  80. LayerBio 
  81. Lodo Therapeutics
  82. M25
  83. Mati Therapeutics
  84. MEAgate
  85. Medical Research Commercialisation Fund (MRCF)
  86. Medis
  87. Merck
  88. Mercury Fund
  89. Meritech Capital Partners
  90. Microchip Technology 
  91. Micropore Technologies
  92. MilliporeSigma
  93. Modulight
  94. Monash Vision Group
  95. Montreaux Growth Partners
  96. MuPharma
  97. Mystic Pharmaceuticals
  98. Nanomerics
  99. Nanyang Technological University
  100. National Institutes of Health (NIH)
  101. Nemera
  102. Neurotech Pharmaceuticals
  103. Nicox
  104. Novaer 
  105. Novaliq
  106. Novartis
  107. NuMedii 
  108. Occlugel
  109. Ocular Therapeutix
  110. Oculex Pharmaceuticals 
  111. Ocumension Therapeutics
  112. Oncimmune
  113. OneOncology
  114. Opharmic Technology
  115. OPHTEC
  116. OrbiMed Advisors
  117. Orsini Specialty Pharmacy
  118. Osage University Partners
  119. Paris Diderot University
  120. PatientFi
  121. Pieris Pharmaceuticals
  122. Pixium Vision
  123. Polaris Partners
  124. PolyActiva  
  125. PSIMedica  
  126. Purdue Pharma
  127. QLT Plug Delivery 
  128. Quadra Logic Tech
  129. Qura
  130. Ramot at Tel Aviv University
  131. Ramscor  
  132. Quadra Logic Technologies 
  133. Re-Vana Therapeutics 
  134. Red Cedar Ventures
  135. Redwood Pharma
  136. Regeneron
  137. Relay Therapeutics
  138. Ribometrix
  139. Ripple Therapeutics
  140. Roche
  141. Rosalind Advisors
  142. Rugen Therapeutics
  143. S K Pharmaceuticals 
  144. Santen Pharmaceutical
  145. Second Sight
  146. Societa Industria Farmaceutica Italiana (SIFI)
  147. Sofinnova Ventures
  148. Sparta Systems
  149. SpringTime Ventures
  150. STADA Arzneimittel
  151. Sun Ophthalmics
  152. SurModics
  153. Sustained Nano Systems
  154. SV Life Sciences
  155. SWK Holdings Corporation
  156. Taiwan Liposome Company
  157. TALLC
  158. TARGET PharmaSolutions
  159. Tempest Therapeutics 
  160. TerraCycle 
  161. TPG Capital
  162. The French National Centre for Scientific Research
  163. Théa Open Innovation
  164. TheraKine 
  165. Tufts University
  166. UCL Business
  167. University of Arizona
  168. University of California
  169. University of California
  170. University of Cincinnati
  171. University of Coimbra
  172. University of Colorado Board of Regents
  173. University of Illinois
  174. University of Maryland
  175. University of Michigan 
  176. University of Northwestern
  177. University of Pennsylvania
  178. University of Pittsburgh 
  179. University of the Witwatersrand
  180. Versant Ventures
  181. ViSci
  182. Vision Source
  183. Visionex Technologies
  184. X Chem
  185. Yuuwa Capital

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com